Literature DB >> 9431833

Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm.

J R Berrazueta1, K Bhagat, P Vallance, R J MacAllister.   

Abstract

AIMS: Endothelin-1 is a potent endogenous vasoconstrictor that acts on the endothelin A (ET[A]) receptor. The dose-response and time-course of the dilator effect of the ET(A) receptor antagonist, BQ-123, was investigated in the forearm of healthy volunteers.
METHODS: Forearm blood flow was measured using mercury-in rubber strain gauge venous occlusion plethysmography.
RESULTS: Following intra-arterial infusion of BQ-123 (50 nmol min-1) for 5 min, forearm blood flow increased by approximately 60% over the next 60 minutes; lower doses were without significant effect. The degree of dilatation was similar to that observed in previous studies using 20-fold larger doses.
CONCLUSIONS: This study confirms that basal endothelin-1 has a role in the physiological regulation of vascular tone. It is possible that at low doses, BQ-123 might be a more sensitive pharmacological tool for the detection of abnormal endothelin-1 mediated constriction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9431833      PMCID: PMC2042881          DOI: 10.1046/j.1365-2125.1997.t01-1-00631.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography.

Authors:  Z S Kyriakides; D T Kremastinos; E Bofilis; D Tousoulis; A Antoniadis; D J Webb
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

2.  Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery.

Authors:  B Prendergast; D E Newby; L E Wilson; D J Webb; P S Mankad
Journal:  Heart       Date:  1999-10       Impact factor: 5.994

Review 3.  Endothelin in cardiovascular control: the role of endothelin antagonists.

Authors:  R R Wenzel; P Czyborra; T Lüscher; T Philipp
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

4.  Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide.

Authors:  A Helmy; D E Newby; R Jalan; P C Hayes; D J Webb
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

5.  Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men.

Authors:  J C Spratt; J Goddard; N Patel; F E Strachan; A J Rankin; D J Webb
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

6.  Endothelins and their inhibition in the human skin microcirculation: ET[1-31], a new vasoconstrictor peptide.

Authors:  Stephen J Leslie; Mamun Q Rahman; Martin A Denvir; David E Newby; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.